EGFR and non-small cell lung carcinoma: In October 2016, FDA has approved pembrolizumab for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (≥50% PD-L1 expression) with no EGFR or ALK genomic tumor aberrations based on the study of KEYNOTE-024 [59].